# Genmab and Incyte Plan Phase 1/2 Trial for KRAS-Mutated Metastatic Colorectal Cancer

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/40650
Published: 2026-10-25T19:04:15.000Z
Updated: 2026-10-25T19:04:15.000Z
Section: Business

> The study will combine petosemtamab and INCB161734 with chemotherapy as a potential first-line treatment.

Genmab A/S and Incyte will test a drug combination in a Phase 1/2 study for metastatic colorectal cancer with a KRAS G12D mutation, evaluating it as a potential first-line treatment.

The combination will include petosemtamab, Genmab’s investigational drug, and INCB161734, Incyte’s investigational drug, alongside chemotherapy.